Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.64 |
| ▸ | GSK3B | P49841 | 12/20 | 0.64 |
| ▸ | WNT1 | P04628 | 7/20 | 0.64 |
| ▸ | CLK2 | P49760 | 2/20 | 0.64 |
| ▸ | CLK3 | P49761 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19540255 | 0.86 | DYRK1A (0.65) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540414 | 0.79 | GSK3B (0.64) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19516591 | 0.78 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540380 | 0.77 | DYRK1A (0.64) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540415 | 0.77 | GSK3B (0.75) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540462 | 0.77 | GSK3B (0.74) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19540260 | 0.75 | DYRK1A (0.70) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916692 | 0.74 | DYRK1A (0.57) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916299 | 0.73 | DYRK1A (0.56) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916182 | 0.72 | DYRK1A (0.77) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189829-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2017-11-02 | — | — | WO | disclosed |